Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs

被引：269

作者：

Van der Veldt, Astrid A. M. ^{[1
]}

Lubberink, Mark ^{[1
,6
]}

Bahce, Idris ^{[2
]}

Walraven, Maudy ^{[3
]}

de Boer, Michiel P. ^{[4
]}

Greuter, Henri N. J. M. ^{[1
]}

Hendrikse, N. Harry ^{[1
,5
]}

Eriksson, Jonas ^{[1
]}

Windhorst, Albert D. ^{[1
]}

Postmus, Pieter E. ^{[2
]}

Verheul, Henk M. ^{[3
]}

Serne, Erik H. ^{[4
]}

Lammertsma, Adriaan A. ^{[1
]}

Smit, Egbert F. ^{[2
]}

机构：

[1] Vrije Univ Amsterdam Med Ctr, Dept Nucl Med & PET Res, NL-1007 MB Amsterdam, Netherlands

[2] Vrije Univ Amsterdam Med Ctr, Dept Pulmonol, NL-1007 MB Amsterdam, Netherlands

[3] Vrije Univ Amsterdam Med Ctr, Dept Med Oncol, NL-1007 MB Amsterdam, Netherlands

[4] Vrije Univ Amsterdam Med Ctr, Dept Internal Med, NL-1007 MB Amsterdam, Netherlands

[5] Vrije Univ Amsterdam Med Ctr, Dept Clin Pharmacol & Pharm, NL-1007 MB Amsterdam, Netherlands

[6] Univ Uppsala Hosp, PET Ctr, S-75185 Uppsala, Sweden

来源：

CANCER CELL | 2012年 / 21卷 / 01期

关键词：

POSITRON-EMISSION-TOMOGRAPHY; MYOCARDIAL BLOOD-FLOW; CELL LUNG-CANCER; CAPILLARY RECRUITMENT; PET/CT SCANNER; BEVACIZUMAB; BREAST; HYPERTENSION; VASCULATURE; DOCETAXEL;

D O I：

10.1016/j.ccr.2011.11.023

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Current strategies combining anti-angiogenic drugs with chemotherapy provide clinical benefit in cancer patients. It is assumed that anti-angiogenic drugs, such as bevacizumab, transiently normalize abnormal tumor vasculature and contribute to improved delivery of subsequent chemotherapy. To investigate this concept, a study was performed in non-small cell lung cancer (NSCLC) patients using positron emission tomography (PET) and radiolabeled docetaxel ([C-11]docetaxel). In NSCLC, bevacizumab reduced both perfusion and net influx rate of [C-11]docetaxel within 5 hr. These effects persisted after 4 days. The clinical relevance of these findings is notable, as there was no evidence for a substantial improvement in drug delivery to tumors. These findings highlight the importance of drug scheduling and advocate further studies to optimize scheduling of anti-angiogenic drugs.

引用

页码：82 / 91

页数：10

共 49 条

[1] AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients [J].